LUOYANG LONGMEN PHARMACEUTICAL CO.,LTD.

Luoyang Longmen Pharmaceutical Group, established in 2013, is located in the Advanced Manufacturing Development Zone of Luoning County, Henan Province. With registered capital of 20 million yuan, it is a comprehensive pharmaceutical company offering integrated services, including R&D, production, sales, promotion, and distribution of pharmaceutical and health products. It is a leading Chinese company specializing in tonic and dialysis APIs, a specialized production base for chemical drugs and traditional Chinese medicine oral liquids, and boasts a comprehensive sales and service team for medical devices and pharmaceutical preparations. The company provides products and services to patients and the public across a wide range of sectors, including synthetic drugs, biopharmaceuticals, API intermediates, nutritional supplements, and pharmaceutical distribution. The company boasts six fully independent production lines equipped with sophisticated equipment and facilities, achieving an annual output of 15,000 tons and employing over 200 people. The company obtained its pharmaceutical production license and GMP certification in 2015, was listed on the National Equities Exchange and Quotations (NEEQ) in August 2019, and entered the Innovation Board (INTL) tier in May 2024. Its stock code is 873356. The company has seven APIs and four excipients: lactic acid, calcium lactate, calcium hydrogen phosphate, sodium lactate solution, calcium acetate, sodium acetate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, lactic acid, and anhydrous sodium carbonate. All products are registered with the National Center for Drug Evaluation and have obtained registration numbers. The company's primary customers include well-known companies such as Fresenius, Harbin Pharmaceutical Sanjin, Jilin Wantong, Jilin Aodong, Hangzhou Minsheng, and Beijing Hanmei. The company also exports to Pakistan, Southeast Asia, and Africa. Relying on scientific and technological advancements, the company was awarded the Luoyang Lactic Acid Biotechnology Engineering Technology Research Center and Henan Province's "Three Regions" Science and Technology Talent Service Base in 2016. In 2019, it was recognized as one of Luoyang's first corporate R&D centers, a Henan Province small and medium-sized technology-based enterprise, and a provincial-level industry-university-research cooperation pilot project. In 2020, it was certified as an Intellectual Property Standardization Enterprise and also received the Henan Engineering R&D Center. In 2021, it became a Henan Province "Specialized, Refined, and Innovative" enterprise and a Luoyang City Intellectual Property Strong Enterprise. It also won the honorary trophy of second prize in the Henan Province Growth Group in the "Phoenix Returns to the Central Plains" Homecoming Entrepreneurship Competition. In 2022, it was recognized as a Luoyang "Hidden Champion" Cultivation Enterprise for the second time, successfully designated as a Luoyang Technology Center, and certified as a Municipal Quality Benchmark Enterprise in 2023. It also won the Excellence Award in the 12th China Innovation and Entrepreneurship Competition in Henan and the 15th Henan Provincial Innovation and Entrepreneurship Competition, among many other honors. To date, the company holds 20 utility models, 5 inventions, and 3 scientific and technological achievements with independent intellectual property rights. Longmen Pharmaceutical will uphold the entrepreneurial spirit of pragmatism, passion, professionalism and innovation, take improving the quality of human life as its lofty mission, and strive to become the development of China's pharmaceutical industry and contribute to the health of mankind.